ArticleScientific reports2025
An explainable transformer model for Alzheimer's disease detection using retinal imaging.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Explainable AI for diabetic retinopathy detection using vision transformers.Scientific reports · 2026Article
- Swin-DRNet: A robust transformer framework for diabetic retinopathy screening under heterogeneous imaging conditions.Scientific reports · 2026Article
- Transformer-Based Deep Learning for Population-Scale Retinal Image Screening of Ophthalmic Disorders.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions worldwide. In the absence of effective treatment options, early diagnosis is crucial for initiating management strategies to delay disease onset and slow down its progression. In this study, we propose Retformer, a novel transformer-based architecture for detecting AD using retinal imaging modalities, leveraging the power of transformers and explainable artificial intelligence. The Retformer model is trained on datasets of different modalities of retinal images from patients with AD and age-matched healthy controls, enabling it to learn complex patterns and relationships between image features and disease diagnosis. To provide insights into the decision-making process of our model, we employ the Gradient-weighted Class Activation Mapping algorithm to visualise the feature importance maps, highlighting the regions of the retinal images that contribute most significantly to the classification outcome. These findings are compared to existing clinical studies on detecting AD using retinal biomarkers, allowing us to identify the most important features for AD detection in each imaging modality. The Retformer model outperforms a variety of benchmark algorithms across different performance metrics by margins of up to 11%.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.